Signal from the log
CONNECTA Therapeutics
3,1 M€ · Early stage · Spain · Biotech
Biotech de Barcelone qui développe CTH120, une gélule contre le syndrome de l'X fragile, maladie génétique sans traitement de la cause. La molécule vise le récepteur TrkB, quand Novartis et Roche avaient échoué sur une autre cible, mGluR5. L'argent finit un essai de phase IIa sur trente hommes, résultats mi 2027.
Article
Announced on , logged by the watch of 10 September 2026.
- Operation
- Funding round
- Announced amount
- 3,1 M€
- Stage
- Early stage
- Country
- Spain
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by Clave Capital , with Inveready , CDTI Innvierte , Prous Institute for Biomedical Research
Provenance
Source fortune
Logged on 10 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.